- Home
- BTAI vs MTNB Comparison
BTAI vs MTNB Comparison
Compare BTAI & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- MTNB
- Stock Information
- Founded
- BTAI 2017
- MTNB 2013
- Country
- BTAI United States
- MTNB United States
- Employees
- BTAI N/A
- MTNB N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- MTNB Health Care
- Exchange
- BTAI Nasdaq
- MTNB Nasdaq
- Market Cap
- BTAI 8.3M
- MTNB 7.9M
- IPO Year
- BTAI 2018
- MTNB N/A
- Fundamental
- Price
- BTAI $5.48
- MTNB $2.36
- Analyst Decision
- BTAI Strong Buy
- MTNB Hold
- Analyst Count
- BTAI 4
- MTNB 1
- Target Price
- BTAI $40.00
- MTNB N/A
- AVG Volume (30 Days)
- BTAI 22.4M
- MTNB 1.2M
- Earning Date
- BTAI 08-12-2025
- MTNB 08-26-2025
- Dividend Yield
- BTAI N/A
- MTNB N/A
- EPS Growth
- BTAI N/A
- MTNB N/A
- EPS
- BTAI N/A
- MTNB N/A
- Revenue
- BTAI $868,000.00
- MTNB N/A
- Revenue This Year
- BTAI N/A
- MTNB N/A
- Revenue Next Year
- BTAI $328.13
- MTNB N/A
- P/E Ratio
- BTAI N/A
- MTNB N/A
- Revenue Growth
- BTAI N/A
- MTNB N/A
- 52 Week Low
- BTAI $1.17
- MTNB $0.47
- 52 Week High
- BTAI $13.36
- MTNB $8.00
- Technical
- Relative Strength Index (RSI)
- BTAI 67.45
- MTNB 86.61
- Support Level
- BTAI $1.30
- MTNB $1.33
- Resistance Level
- BTAI $8.08
- MTNB $1.85
- Average True Range (ATR)
- BTAI 1.23
- MTNB 0.28
- MACD
- BTAI 0.33
- MTNB 0.13
- Stochastic Oscillator
- BTAI 61.65
- MTNB 67.88
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.